Linghe Zang

Linghe Zang

Auto-generated profile, based on publicly available information

Linghe Zang

Institute of Life science and Bio‐pharmaceuticals Traditional Chinese Medicine College Shenyang Pharmaceutical University Liaoning China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
LZLinghe Zang
Linghe Zang
FTFangyuan Tian
Fangyuan Tian
YYYuancheng Yao
Yuancheng Yao
YCYiran Chen
Yiran Chen
YSYuan Shen
Yuan Shen
JLJincai Lu
Jincai Lu
Qianliexin capsule (QLX) is a standardized traditional Chinese herbal preparation that has long been used to treat chronic non‐bacterial prostatitis (CNP) and benign prostatic hyperplasia (BPH). This study investigated the anti‐inflammatory activity of QLX in improving lower urinary tract symptoms (LUTS) associated with CNP and BPH. Rat models of CNP and BPH were induced by oestradiol or testosterone (hormonal imbalance) or chemical inflammation (carrageenan). QLX significantly relieved LUTS in CNP and BPH rat model by reducing prostate enlargement, epithelial thickness, pain response time, urine volume and bleeding time, and by improving prostatic blood flow. The expression of the pro‐inflammatory cytokines interleukin (IL)‐1β and tumour necrosis factor (TNF)‐α, the pro‐inflammatory transcription factor nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB), and inflammasome components (NLRP3, caspase‐1 and ASC) in CNP and BPH tissues was reduced by QLX addition. QLX treatment was followed by reduced cellular malondialdehyde and increased superoxide dismutase, catalase and glutathione peroxidase activity, consistent with antioxidant activity. Increases in Beclin‐1 expression and the LC3II/I ratio following QLX treatment indicated that autophagy had been induced. QLX relieved LUTS in CNP and BPH rat models by inhibiting inflammation. The underlying mechanisms included inhibition of inflammasome activation, NF‐κB activation, oxidant stress and autophagy.

5 July 2013 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
WLWeiwei Liu
Weiwei Liu
WOWuxiyar Otkur
Wuxiyar Otkur
YZYuning Zhang
Yuning Zhang
QLQiuyuan Li
Qiuyuan Li
YYYuanchao Ye
Yuanchao Ye
TITakashi Ikejima
Takashi Ikejima
Ultraviolet B (UVB) is a major cause of skin inflammation, leading to skin damage. Our previous in vivo study revealed that a natural flavonoid silibinin had marked anti‐inflammatory effect on UVB‐exposed murine skin. UVB exposure caused reduced autophagy in epidermis while it promoted autophagy in dermis. Nevertheless, silibinin inhibited the inflammatory flux in the skin epidermis as well as dermis through the modulation of autophagy. In order to elucidate the underlying protective mechanisms of silibinin for UVB damage on skin, separate studies on epidermis and dermis are helpful. Derived from the normal tissue of the mouse, L929 cells are capable of representing some characteristics of dermal cells. UVB irradiation caused L929 cell apoptosis in a time‐ and dose‐dependent manner. Ataxia‐telangiectasia‐mutated (ATM) protein and p53 were activated to cause cell apoptosis, accompanying upregulation of the autophagic flux. The pharmacological inhibition of ATM, p53 and autophagy or the transfection with autophagy‐associated protein‐targeted small interfering RNAs showed that the UVB‐activated ATM‐p53 axis and autophagy formed a positive feedback loop, which synergistically promoted cell apoptosis. Silibinin treatment simultaneously repressed the activation of ATM‐p53 and autophagy and thereby protected UVB‐irradiated L929 cells from apoptotic death.

11 May 2020 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
HHHui-Ming Hua
Hui-Ming Hua
YWYan Wang
Yan Wang
XGXiang Gao
Xiang Gao
SXShengtao Xu
Shengtao Xu
LZLinghe Zang
Linghe Zang
DLDahong Li
Dahong Li
First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study. HAO472 hewed out new avenues to explore the therapeutic properties of oridonin derivatives and develop promising treatment of cancer originated from naturally derived drug candidates. Herein, we sought to overview recent progress of the synthetic, physiological, and pharmacological investigations of oridonin and its derivatives, aiming to disclose the therapeutic potentials and broaden the platform for the discovery of new anticancer drugs.